ArcticZymes Technologies (AZT) 주식 개요
생명과학 회사인 ArcticZymes Technologies ASA는 노르웨이, 독일, 리투아니아, 프랑스, 이탈리아, 영국, 기타 유럽, 미국 및 전 세계에서 분자 연구, 체외 진단 및 바이오 제조에 사용되는 재조합 효소를 개발, 제조 및 상업화하는 회사입니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 AZT에 대한 위험이 감지되지 않았습니다.
AZT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ArcticZymes Technologies ASA 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | NOK 20.60 |
| 52주 최고가 | NOK 31.40 |
| 52주 최저가 | NOK 15.00 |
| 베타 | 0.51 |
| 1개월 변동 | -5.07% |
| 3개월 변동 | -12.34% |
| 1년 변동 | 30.38% |
| 3년 변동 | -52.31% |
| 5년 변동 | -76.91% |
| IPO 이후 변동 | -17.60% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).내러티브 업데이트 • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).Recent updates
내러티브 업데이트 • Apr 27
AZT: Enzyme Platform Expansion And Investor Day Will Support Future Upside
Analysts have slightly reduced their price target on ArcticZymes Technologies from NOK 32.50 to NOK 32.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation (Key Developments).내러티브 업데이트 • Apr 12
AZT: Enzyme Platform Scaling And Analyst Day Will Support Future Upside
Analysts now keep their price target for ArcticZymes Technologies steady at NOK 32.50, reflecting largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in their models. What's in the News ArcticZymes Technologies plans an Analyst/Investor Day to outline how the company has completed its commercial transformation and is now focused on scaling its enzyme platform across biomanufacturing and molecular tool markets (Key Developments).내러티브 업데이트 • Mar 29
AZT: Enzyme Platform Scaling Across Biomanufacturing And Molecular Tools Will Drive Future Upside
Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.5, noting only minor adjustments to factors such as the discount rate, revenue growth assumptions and future P/E that do not materially affect their overall assessment of fair value. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day focused on how the company has completed its commercial transformation.내러티브 업데이트 • Mar 14
AZT: Enzyme Platform Scaling Across Biomanufacturing Markets Will Support Future Upside
Analysts have slightly adjusted their price target for ArcticZymes Technologies to NOK 32.50, reflecting modest tweaks to their discount rate, revenue growth expectations, profit margin assumptions, and future P/E inputs, while keeping their overall fair value view unchanged. What's in the News ArcticZymes Technologies is holding an Analyst and Investor Day to explain how it has completed its commercial transformation.내러티브 업데이트 • Feb 27
AZT: Enzyme Platform Scaling Across Biomanufacturing Will Drive Future Upside
Analysts have trimmed their price target for ArcticZymes Technologies to NOK 32.5 from NOK 40.20. They cite slightly lower assumptions for long term revenue growth, profit margin and future P/E, along with a modestly higher discount rate in their models.분석 기사 • Feb 15
Results: ArcticZymes Technologies ASA Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, ArcticZymes Technologies ASA ( OB:AZT ) just kicked off its latest full-year results with some very...내러티브 업데이트 • Feb 13
AZT: Buyback Program And Platform Scaling Will Support Future Upside
Analysts have nudged their price target for ArcticZymes Technologies to NOK32.50 from NOK32.00, reflecting updated views on slightly adjusted revenue growth, profit margin assumptions and a higher future P/E multiple. What's in the News ArcticZymes Technologies plans an Analyst and Investor Day to explain how it has completed its commercial transformation and is now focused on scaling its enzyme platform across high growth biomanufacturing and molecular tool markets (Key Developments).내러티브 업데이트 • Jan 23
AZT: European Distribution Deal And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for ArcticZymes Technologies steady at NOK 32.0 per share, indicating only minor adjustments in assumptions such as the discount rate and future P/E, rather than any major change in their overall view. What's in the News ArcticZymes Technologies ASA plans to start share repurchases on November 25, 2025, under an AGM mandate from May 27, 2025.분석 기사 • Jan 08
Subdued Growth No Barrier To ArcticZymes Technologies ASA (OB:AZT) With Shares Advancing 25%
Those holding ArcticZymes Technologies ASA ( OB:AZT ) shares would be relieved that the share price has rebounded 25...내러티브 업데이트 • Jan 07
AZT: European Distribution Agreement And Share Buyback Will Support Future Upside
Analysts have maintained their fair value estimate for ArcticZymes Technologies at $32.0. They cite unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for leaving their price target intact. What's in the News ArcticZymes Technologies ASA started a share repurchase program on November 25, 2025, under an authorization from the May 27, 2025 Annual General Meeting.분석 기사 • Jan 07
Are Investors Undervaluing ArcticZymes Technologies ASA (OB:AZT) By 50%?
Key Insights The projected fair value for ArcticZymes Technologies is kr45.44 based on 2 Stage Free Cash Flow to Equity...내러티브 업데이트 • Dec 23
AZT: European Distribution Deal And Buyback Program Will Drive Future Upside
Analysts have modestly raised their price target on ArcticZymes Technologies to NOK 32.00, reflecting slightly lower perceived risk and continued confidence in the company’s robust growth and margin profile. What's in the News ArcticZymes Technologies has commenced a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90 percent of outstanding share capital.내러티브 업데이트 • Dec 09
AZT: European Distribution Deal Will Drive Future Demand And Margin Strength
Narrative Update on ArcticZymes Technologies Analysts have maintained their price target for ArcticZymes Technologies at NOK 32.00, reflecting largely unchanged assumptions on fair value, revenue growth, and profit margins, while only slightly adjusting the discount rate and future price to earnings expectations. What's in the News ArcticZymes Technologies ASA has launched a share repurchase program starting November 25, 2025, allowing buybacks of up to 2,500,000 shares, or 4.90% of outstanding capital, with authorization valid until the 2026 AGM or June 30, 2026, whichever comes first (Key Developments).내러티브 업데이트 • Nov 25
AZT: Exclusive Distribution Partnership Will Drive European Expansion And Strengthen Margins
Analysts have adjusted their price target for ArcticZymes Technologies, keeping it at NOK 32.00. This decision is based on continued expectations for strong profit margins along with a more cautious perspective on future earnings multiples.분석 기사 • Nov 20
More Unpleasant Surprises Could Be In Store For ArcticZymes Technologies ASA's (OB:AZT) Shares After Tumbling 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...내러티브 업데이트 • Nov 10
AZT: Exclusive Distribution Deal Will Improve Profitability And European Market Presence
Analysts have maintained their fair value estimate for ArcticZymes Technologies at NOK 32.00, citing stable profit margin improvements and changes in the revenue growth outlook as key factors in their latest assessment. What's in the News ArcticZymes Technologies ASA and Brenntag Specialties Pharma have signed an exclusive distribution agreement for SAN-HQ and M-SAN enzymes across Europe.내러티브 업데이트 • Oct 27
Precision Medicine Will Continue Advancing Through Biomanufacturing And Gene Therapies
Analysts have maintained their fair value price target for ArcticZymes Technologies at NOK 32.00. They cite stable revenue growth and profitability projections as the basis for leaving their outlook unchanged.내러티브 업데이트 • Oct 13
Biomanufacturing And Gene Therapies Will Expand Precision Medicine
Analysts have raised their price target for ArcticZymes Technologies from NOK 29 to NOK 32. They cite updated growth forecasts and stronger margin expectations as key factors in the upward revision.내러티브 업데이트 • Aug 15
Biomanufacturing Advances Will Unlock Global Market Access
The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50. What's in the News Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.분석 기사 • Aug 15
What ArcticZymes Technologies ASA's (OB:AZT) 50% Share Price Gain Is Not Telling You
ArcticZymes Technologies ASA ( OB:AZT ) shareholders have had their patience rewarded with a 50% share price jump in...분석 기사 • Mar 11
ArcticZymes Technologies ASA's (OB:AZT) 33% Share Price Surge Not Quite Adding Up
The ArcticZymes Technologies ASA ( OB:AZT ) share price has done very well over the last month, posting an excellent...분석 기사 • Feb 15
ArcticZymes Technologies ASA's (OB:AZT) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights The projected fair value for ArcticZymes Technologies is kr27.08 based on 2 Stage Free Cash Flow to Equity...
새로운 내러티브 • Jan 20
Transition To Solution Provider Will Accelerate Market Penetration By Late 2025
ArcticZymes is shifting from raw materials to solutions, aiming for revenue growth through closer customer interactions and market penetration by late 2025.분석 기사 • Nov 28
Take Care Before Jumping Onto ArcticZymes Technologies ASA (OB:AZT) Even Though It's 25% Cheaper
To the annoyance of some shareholders, ArcticZymes Technologies ASA ( OB:AZT ) shares are down a considerable 25% in...분석 기사 • Nov 12
Analysts Are More Bearish On ArcticZymes Technologies ASA (OB:AZT) Than They Used To Be
Market forces rained on the parade of ArcticZymes Technologies ASA ( OB:AZT ) shareholders today, when the analysts...분석 기사 • Nov 09
ArcticZymes Technologies ASA Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its...분석 기사 • Aug 31
The Price Is Right For ArcticZymes Technologies ASA (OB:AZT) Even After Diving 28%
ArcticZymes Technologies ASA ( OB:AZT ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Aug 30
ArcticZymes Technologies' (OB:AZT) Solid Earnings May Rest On Weak Foundations
ArcticZymes Technologies ASA's ( OB:AZT ) healthy profit numbers didn't contain any surprises for investors. We think...분석 기사 • Aug 25
ArcticZymes Technologies ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a sad week for ArcticZymes Technologies ASA ( OB:AZT ), who've watched their investment drop 13% to kr21.00...분석 기사 • May 12
Earnings Miss: ArcticZymes Technologies ASA Missed EPS By 17% And Analysts Are Revising Their Forecasts
Last week, you might have seen that ArcticZymes Technologies ASA ( OB:AZT ) released its quarterly result to the...분석 기사 • Feb 08
ArcticZymes Technologies' (OB:AZT) Shareholders Have More To Worry About Than Only Soft Earnings
Last week's earnings announcement from ArcticZymes Technologies ASA ( OB:AZT ) was disappointing to investors, with a...분석 기사 • Feb 04
ArcticZymes Technologies ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in ArcticZymes Technologies ASA ( OB:AZT ) shares in the week since it released its yearly...분석 기사 • Feb 02
Investors Aren't Buying ArcticZymes Technologies ASA's (OB:AZT) Revenues
When close to half the companies operating in the Biotechs industry in Norway have price-to-sales ratios (or "P/S...주주 수익률
| AZT | NO Biotechs | NO 시장 | |
|---|---|---|---|
| 7D | 4.0% | -0.6% | 0.1% |
| 1Y | 30.4% | 49.9% | 19.0% |
수익률 대 산업: AZT은 지난 1년 동안 49.9%의 수익을 기록한 Norwegian Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: AZT은 지난 1년 동안 19%를 기록한 Norwegian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| AZT volatility | |
|---|---|
| AZT Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in NO Market | 11.8% |
| 10% least volatile stocks in NO Market | 3.2% |
안정적인 주가: AZT는 지난 3개월 동안 Norwegian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: AZT의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1990 | 51 | Michael Akoh | www.arcticzymes.com |
생명과학 회사인 ArcticZymes Technologies ASA는 노르웨이, 독일, 리투아니아, 프랑스, 이탈리아, 영국, 기타 유럽, 미국 및 전 세계에서 분자 연구, 체외 진단 및 바이오 제조에 사용되는 재조합 효소를 개발, 제조 및 상업화합니다. 이 회사는 생어 시퀀싱 및 차세대 시퀀싱 프로세스 전 정화를 위한 새우 알칼리성 포스파타제, 오염된 dU-DNA 제거를 위한 바이러스 및 기타 분자 진단 분석에 사용되는 대구 UNG, 바이러스 벡터, 재조합 단백질 및 기타 시약 제조 중 핵산 제거를 위한 염 활성 뉴클레아제, 이중 가닥 DNA 제거용 이중 가닥 특이 DNase 및 파생 키트 등을 제공합니다. 또한 생명과학, 분자 진단, NGS 및 합성 생물학 기술 개발을 위한 DNA/RNA 중합효소, 미생물 진단 및 액체 생검을 위한 프로테아제, 핵산 결합을 위한 리가제 등을 제공합니다.
ArcticZymes Technologies ASA 기초 지표 요약
| AZT 기초 통계 | |
|---|---|
| 시가총액 | NOK 1.05b |
| 순이익 (TTM) | NOK 13.43m |
| 매출 (TTM) | NOK 128.37m |
78.3x
주가수익비율(P/E)8.2x
주가매출비율(P/S)AZT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| AZT 손익계산서 (TTM) | |
|---|---|
| 매출 | NOK 128.37m |
| 매출원가 | NOK 6.14m |
| 총이익 | NOK 122.23m |
| 기타 비용 | NOK 108.80m |
| 순이익 | NOK 13.43m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 14, 2026
| 주당순이익(EPS) | 0.26 |
| 총이익률 | 95.22% |
| 순이익률 | 10.46% |
| 부채/자본 비율 | 0% |
AZT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/03 09:16 |
| 종가 | 2026/06/03 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ArcticZymes Technologies ASA는 6명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Carnegie |
| Viktor Sundberg | Nordea Markets |